Jubilant Pharmova (JUBLPHARMA) — Board Meeting

📢 Key Event
Board recommends ₹5 final dividend per share for FY 2025-26, pending AGM approval

🔄 What Changed
Dividend amount announced and TDS withholding rules detailed for residents and non-residents

🔮 What's Next
Submit PAN or exemption documents by August 14, 2026, to avoid 20% TDS; tax treatment depends on documentation compliance

💡 Investor Takeaway
Shareholders must submit required tax documents by August 14 to avoid higher TDS on dividend income

Jubilant Pharmova announced a final dividend of ₹5 per share for FY 2025-26, payable to shareholders on record as of July 24, 2026, subject to AGM approval. The company clarified TDS withholding rules under the Income Tax Act, 2025, including resident and non-resident tax rates, required documentation, and deadlines for submitting PAN or exemption forms by August 14, 2026, to claim lower or nil tax deductions.

📄 View Original Announcement (PDF)

📊 Stock Analysis — JUBLPHARMA ✨ Ask AI About This

About Jubilant Pharmova Limited (JUBLPHARMA)

Healthcare · Pharmaceuticals · Listed on NSE

Market Cap: ₹14,469.9 Cr P/E: 40.9 ROE: 5.0% ROCE: 7.4% Div Yield: 0.55%

View full JUBLPHARMA stock details →

📡 Get AI alerts when JUBLPHARMA files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track JUBLPHARMA — Free

💡 Ask AI about this filing

"What is the record date for dividend eligibility?" "How will non-resident tax treaty benefits be applied?" "What is the impact of higher TDS on net dividend yield?"

Ask AI Free →

📊 More JUBLPHARMA filings

See all JUBLPHARMA filings →

🔥 Also filed on 1 August 2026

PNCINFRA PNC Infratech Limited Announcement LATENTVIEW Latent View Analytics Limited Financial Results NIITLTD NIIT Limited Announcement RVNL Rail Vikas Nigam Limited Annual Report RVNL Rail Vikas Nigam Limited Annual Report BILVYAPAR BIL VYAPAR LIMITED Announcement

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when JUBLPHARMA files new disclosures

Track JUBLPHARMA filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track JUBLPHARMA — Free

Free account · 2 AI queries/day

About · Privacy Policy · Terms of Service · Pricing

Today's Announcements · Screener · Insights · AI Chat

Data provided by CMOTS Internet Technologies Pvt Ltd